arXiv · 2004.12028
Two-Stage Penalized Regression Screening to Detect Biomarker-Treatment Interactions in Randomized Clinical Trials
Abstract
High-dimensional biomarkers such as genomics are increasingly being measured in randomized clinical trials. Consequently, there is a growing interest in developing methods that improve the power to detect biomarker-treatment interactions. We adapt recently proposed two-stage interaction detecting procedures in the setting of randomized clinical trials. We also propose a new stage 1 multivariate screening strategy using ridge regression to account for correlations among biomarkers. For this multivariate screening, we prove the asymptotic between-stage independence, required for family-wise error rate control, under biomarker-treatment independence. Simulation results show that in various scenarios, the ridge regression screening procedure can provide substantially greater power than the traditional one-biomarker-at-a-time screening procedure in highly correlated data. We also exemplify our approach in two real clinical trial data applications.
Explore related subjects
Keep this discovery
Jixiong Wang, Ashish Patel, James M. S. Wason, Paul J. Newcombe. 2020-04-25. Two-Stage Penalized Regression Screening to Detect Biomarker-Treatment Interactions in Randomized Clinical Trials. https://doi.org/10.1111/biom.13424
Cite the original work for its findings. Save a collection to share your selection of sources.